Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

NCT04881240 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia, in Relapse
Acute Lymphoblastic Leukemia, Refractory
Pediatric ALL

Interventions

BIOLOGICAL: CD19-CAR(Mem) T-cells
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna
DEVICE: CliniMACS
PROCEDURE: Leukapheresis

Sponsor

St. Jude Children's Research Hospital